Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 versus docetaxel or pemetrexed in previously treated advanced or metastatic nonsquamous NSCLC with EGFR mutations or other genomic alterations
2023-503539-16-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall survival in participants with NSCLC with EGFR mutations. Planned start Sep 2024; status: authorised.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503539-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503539-16-00.